# Diabetes Hub Monitor Report — 2026-05-07

**Scan time:** 2026-05-07 07:39 UTC
**Previous monitor report:** 2026-05-06
**Workspace root:** `Diabetes_Research/`
**Script outputs reviewed:** `hub_monitor_report.md`, `clinical_trials_latest.json` (786 trials), `pubmed_recent_latest.json` (144 papers, 16 domains), `literature_gap_report.md`, `literature_gap_data.json`

---

## File System Status

| File | Last Modified | Status |
|------|---------------|--------|
| `hub_monitor_report.md` | 2026-05-07 07:05 | Fresh (today) |
| `clinical_trials_latest.json` | 2026-05-07 07:04 | Fresh (today) |
| `clinical_trials_snapshot_2026-05-07.json` | 2026-05-07 07:04 | Fresh (today) |
| `pubmed_recent_latest.json` | 2026-05-07 07:05 | Fresh (today) |
| `pubmed_recent_snapshot_2026-05-07.json` | 2026-05-07 07:05 | Fresh (today) |
| `pubmed_recent_summary.md` | 2026-05-07 07:05 | Fresh (today) |
| `literature_gap_report.md` | 2026-05-05 08:12 | Fresh (2 days) |
| `literature_gap_data.json` | 2026-04-20 15:35 | **STALE (17 days)** |

Hub-wide flag from `hub_monitor.py`: 573 result files older than 14 days. Most are dated daily snapshots that are intentionally archived — not action items. The actionable stale file is `literature_gap_data.json` (the underlying PubMed pair counts that feed the gap report). The Markdown gap report was regenerated 2026-05-05 but uses the older underlying data.

There was no daily monitor scan on 2026-05-06 (no `clinical_trials_snapshot_2026-05-06.json` or `pubmed_recent_snapshot_2026-05-06.json`), so today's `hub_monitor_report.md` diffs against 2026-05-05.

---

## Clinical Trial Changes

**Snapshot diff (2026-05-05 → 2026-05-07, from `hub_monitor_report.md`):** 4 new, 1 removed, 2 status changes, 0 newly posted results.

**Status changes promoted to RECRUITING:**
- **NCT07415954** — NOT_YET_RECRUITING → RECRUITING. Novo Nordisk Phase 2 dose-finding study of NNC0662-0419.
- **NCT07135531** — NOT_YET_RECRUITING → RECRUITING. CGM in an Underserved Population (health-equity-aligned).

**7-day delta (vs. 2026-04-30 snapshot):** 13 new trial records, 3 removed, 4 status changes, 0 newly posted results. Additional status changes seen in the 7-day window:
- NCT07321678: RECRUITING → ACTIVE_NOT_RECRUITING (a tirzepatide tolerability study)
- NCT07355270: NOT_YET_RECRUITING → RECRUITING (RF vapor ablation pilot, U.S.)

**Active Phase 3 RECRUITING trials of strategic interest (from `clinical_trials_latest.json`):**

| NCT | Sponsor | Therapy / Topic |
|-----|---------|-----------------|
| NCT06832410 | Vertex | VX-880 (zimislecel) — pivotal Phase 3, T1D islet cell therapy |
| NCT04786262 | Vertex | VX-880 — supporting Phase 1/2/3 |
| NCT07222332 | Eli Lilly | Baricitinib for beta-cell preservation, pediatric T1D |
| NCT07222137 | Eli Lilly | Baricitinib to delay Stage 3 T1D in adults |
| NCT07088068 | Sanofi | Teplizumab head-to-head comparator |
| NCT07076199 | Novo Nordisk | Insulin icodec (weekly) — late-stage |
| NCT06334133 | vTv Therapeutics | Cadisegliatin (glucokinase activator) adjunctive in T1D |
| NCT07351058 | Roche | Enicepatide (RO7795068) |

Vertex, Lilly, Novo, Sanofi, and Roche are all running pivotal trials whose readouts will define near-term competitive landscape. Cadisegliatin is the only active Phase 3 in the *glucokinase activator* class — directly relevant to several Tier-1 gaps in our doctrine (see "Gap Alignment" below).

**Recently completed trials with results posted in the last ~14 days (high-relevance subset):**
- NCT05971940 (2026-04-22) — Orforglipron in T2D + obesity (Lilly Phase 3, ACHIEVE program)
- NCT05649137 (2026-04-27) — Semaglutide in excess weight + T2D (Novo Phase 3)
- NCT05823948 (2026-04-30) — Flash glucose with once-weekly insulin icodec (Novo)
- NCT05462756 — Insulin efsitora alfa (Lilly, weekly basal)

Results-posted volume to ClinicalTrials.gov in the last 30 days: **21 trials**. None are net-new since the previous monitor scan (2026-05-05).

---

## PubMed Highlights

Latest snapshot (`pubmed_recent_latest.json`): 144 unique papers across 16 alert domains, 30-day lookback. **100 papers are new vs. the 2026-04-30 snapshot** (high turnover — consistent with the 30-day rolling window).

**Cross-domain papers (10 total — highest priority per doctrine):** Standout new ones since 2026-05-05:
- **PMID 42089665** — *VEGFA-Targeted M3-F4 Ionizable Lipid Nanoparticles Improve Diabetic Retinopathy* — Domains: Gene Therapy × Complications. Bridges two Tier-1 priority areas.
- **PMID 42089922** — *Prognostic Imaging Biomarkers in Diabetic Macular Edema Treated with Anti-VEGF: A Multicenter AI Perspective* — Domains: AI/ML × Biomarker.
- **PMID 42085931** — *Multi-omics analysis of the gut microbiome and carotid artery atherosclerosis in men with and without diabetes* — Domains: Microbiome × Multi-Omics.
- **PMID 42051156** — *Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus* — Domains: T1D Immunotherapy × Key Therapy (teplizumab). Likely cited in our teplizumab decision-prep file.
- **PMID 42082522** — *Sex-specific microbial and tryptophan signatures of depression* — Domains: AI/ML × Microbiome.

**Key-therapy mentions (last 30 days):**
- **teplizumab:** 3 papers (PMIDs 42051156, 41796109, 41535597) — all clinical-practice/real-world. Aligns with the recent FDA expansion to ages 1+ (see Breaking News).
- **orforglipron:** 3 papers — bioequivalence study (PK), and two methodological critiques in *Acta Diabetologica*.
- **retatrutide:** 2 papers.
- **baricitinib:** 2 papers (consistent with two Lilly Phase 3 starts above).
- **dapagliflozin:** 24 hits (5 detailed) — note expansion into HIV-cardiometabolic territory (PMID 42054528, 42050587).
- **icodec:** 4 hits — one cost-utility paper, plus the NCT05823948 results.
- **zimislecel, CagriSema:** 0 PubMed hits in 30-day window despite active pivotal trials. Watch for pre-ADA-2026 publications.

**Domain-volume notes:** AI/ML (190 indexed in 30 days) and Biomarker (143) continue to dominate. Drug Repurposing (4) and LADA (2) remain very low — consistent with the gap report.

---

## Gap Analysis Summary

Top 5 gap-scored intersections (from `literature_gap_report.md`, generated 2026-05-05 from PubMed pair counts dated 2026-04-20):

1. **Beta Cell Regen × Health Equity** (Gap 100, 0 joint pubs)
2. **Insulin Resistance × Islet Transplant** (Gap 100, 1 joint pub)
3. **Islet Transplant × Drug Repurposing** (Gap 100, 0)
4. **Islet Transplant × Health Equity** (Gap 100, 0)
5. **Gene Therapy × LADA** (Gap 100, 0)

**Tier-1 alignment with `RESEARCH_DOCTRINE.md`/`CONTRIBUTION_STRATEGY.md`:** The Vertex VX-880 pivotal program plus zero Health-Equity work on islet transplant or beta-cell regen is a defensible gap to occupy — exactly the "access analysis of emerging cell therapies" frame already in the report. The Drug-Repurposing × Islet-Transplant pair is also Tier-1 aligned and has zero joint pubs.

**Caveat:** Gap data is 17 days old. The five top intersections are deep enough (zero or near-zero joint pubs) that they are robust to small refresh deltas, but the Markdown report shouldn't be quoted as "current" until `project1_literature_gap_analysis.py` is re-run.

---

## Breaking News (Web Check, last 7 days)

- **FDA expanded Tzield (teplizumab-mzwv) indication** to as young as age 1 to delay onset of stage 3 T1D in stage-2 patients (Sanofi press release, 2026-04-22). Direct material impact on our teplizumab tracking and supports the three new teplizumab PubMed papers above. **Evidence level: GOLD (regulatory action).**
- **Novo Nordisk Ozempic tablets** (1.5 / 4 / 9 mg, oral semaglutide for T2D) became commercially available in the U.S. on **2026-05-04** — the only FDA-approved oral peptide GLP-1 medication.
- **MannKind Afrezza pediatric sBLA** has a **PDUFA date of 2026-05-29** — first needle-free pediatric inhaled insulin if approved.
- **Lilly Foundayo (orforglipron)** has been FDA-approved as the first oral GLP-1 pill for weight loss with no food/water restriction (companion to ACHIEVE-1 program). Reinforces the 3 orforglipron PubMed hits.
- **Boehringer Ingelheim survodutide** SYNCHRONIZE-1 Phase 3 met co-primary endpoints (16.6% weight loss vs. 3.2% placebo at 76 weeks). Full data at ADA 2026 (June). **Worth pre-flagging tracker for ADA-2026 readouts.**
- **Langlara (insulin glargine-aldy)** approved 2026-04-29 as interchangeable Lantus biosimilar.

Skipped: routine product news, blog speculation, and conference previews not tied to disclosed data.

---

## Recommended Actions

1. **Re-run gap analysis** — `python project1_literature_gap_analysis.py`. The underlying `literature_gap_data.json` is 17 days old and the Markdown report cites pair counts as of 2026-04-20.
2. **Update tracker (`Diabetes_Research_Tracker.xlsx`)** with three near-term events:
   - Tzield pediatric expansion (FDA action 2026-04-22) — update teplizumab row + the `teplizumab_sNDA_decision_prep.md` analysis.
   - MannKind Afrezza PDUFA 2026-05-29 — add to upcoming-decisions watchlist.
   - Boehringer survodutide SYNCHRONIZE-1 → ADA-2026 readout.
3. **Add to literature review queue** (cross-domain papers, ranked):
   - PMID 42089665 — VEGFA LNP for retinopathy (Gene Therapy × Complications)
   - PMID 42051156 — Teplizumab Stage-2 consensus (T1D Immunotherapy × therapy)
   - PMID 42089922 — DME imaging biomarkers + AI (AI/ML × Biomarker)
   - PMID 42085931 — Microbiome multi-omics carotid atherosclerosis
4. **Address scan gap:** No 2026-05-06 snapshot exists for clinical trials or PubMed (last snapshots: 2026-05-05, then 2026-05-07). Confirm `refresh.ps1` ran on 2026-05-06 or note the missed day.
5. **Tier-1 gap pursuit:** Consider drafting a contribution scope note for *Beta Cell Regen × Health Equity* (Gap 100, 0 joint pubs) — VX-880 Phase 3 is now actively enrolling and any equity analysis published before commercial launch would have first-mover advantage. Aligns with `CONTRIBUTION_STRATEGY.md`.
6. **Pre-ADA-2026 watch:** Set a reminder to re-scan ClinicalTrials.gov + PubMed in the week before ADA 2026 (June). Expected major readouts: survodutide full SYNCHRONIZE-1, orforglipron ACHIEVE late-breakers, Vertex VX-880 updates.

---

*Generated automatically by `diabetes-hub-monitor` scheduled task. Per Research Doctrine: web-sourced regulatory news is GOLD-level evidence; PubMed signal is BRONZE until cross-validated; gap classifications remain BRONZE pending domain-expert review. No files were modified by this run.*

**Sources (web check):**
- [FDA Drug Approval Decisions Expected in May 2026 — Cardiology Advisor](https://www.thecardiologyadvisor.com/news/fda-drug-approval-decisions-expected-in-may-2026/)
- [Sanofi: Tzield approved to delay stage 3 T1D in young children](https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-3278650)
- [Novo Nordisk: Ozempic pill availability announcement](https://www.prnewswire.com/news-releases/novo-nordisks-ozempic-pill-the-only-fda-approved-oral-peptide-glp-1-medication-for-adults-with-type-2-diabetes-soon-to-be-available-in-the-us-302760106.html)
- [Eli Lilly: Foundayo (orforglipron) approval](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill)
- [Boehringer Ingelheim: SYNCHRONIZE-1 Phase 3 results](https://www.boehringer-ingelheim.com/us/human-health/metabolic-diseases/results-phase-iii-synchronize-1-obesity-trial)
- [FDA: First Generic Dapagliflozin Tablets](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-first-generic-dapagliflozin-tablets)
